Pascal and Francis Bibliographic Databases

Help

Search results

Your search

au.\*:("KANTARJIAN, Hagop")

Document Type [dt]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 727

  • Page / 30
Export

Selection :

  • and

New advances in the treatment of hematologic malignancies: focus on topoisomerase I inhibitorsKANTARJIAN, Hagop.Seminars in hematology. 1998, Vol 35, Num 3, issn 0037-1963, 40 p., SUP4Serial Issue

Hematologic malignancies: is there a role for topoisomerase-I inhibitors?KANTARJIAN, Hagop.Seminars in hematology. 1999, Vol 36, Num 4, issn 0037-1963, 34 p., SUP8Serial Issue

Introduction: Targeting Different Pathways to Prevent Tumor Cell DevelopmentKANTARJIAN, Hagop M.Seminars in oncology. 2009, Vol 36, Num 2, issn 0093-7754, S1-S5, SUP1Article

Purine nucleoside phosphorylase (PNP): a novel target in leukemias and lymphomasKANTARJIAN, Hagop M.Seminars in oncology. 2007, Vol 34, Num 6, issn 0093-7754, 41 p., SUP5Serial Issue

Targeting Different Pathways to Prevent Tumor Cell DevelopmentKANTARJIAN, Hagop M.Seminars in oncology. 2009, Vol 36, Num 2, issn 0093-7754, 59 p., SUP1Serial Issue

Chronic myeloid leukemia: 2012 Update on diagnosis, monitoring, and managementJABBOUR, Elias; KANTARJIAN, Hagop.American journal of hematology. 2012, Vol 87, Num 11, pp 1038-1045, issn 0361-8609, 8 p.Article

The clinical pharmacology of topoisomerase I inhibitorsABANG, A. M.Seminars in hematology. 1998, Vol 35, Num 3, pp 13-21, issn 0037-1963, SUP4Article

Novel therapies for myelodysplastic syndromesFADERL, Stefan; KANTARJIAN, Hagop M.Cancer. 2004, Vol 101, Num 2, pp 226-241, issn 0008-543X, 16 p.Article

Molecular genetics and therapy of leukemiaFREIREICH, Emil J; KANTARJIAN, Hagop.Cancer treatment and research. 1996, Vol 84, issn 0927-3042, 343 p.Serial Issue

The role of topoisomerase-I inhibitors in the treatment of non-Hodgkin's lymphomaCABANILLAS, F.Seminars in hematology. 1999, Vol 36, Num 4, pp 11-15, issn 0037-1963, SUP8Article

New developments in the treatment of acute myeloid leukemia : Focus on topotecanKANTARJIAN, H.Seminars in hematology. 1999, Vol 36, Num 4, pp 16-25, issn 0037-1963, SUP8Article

Induction of apoptosis by topotecan : Implications for the treatment of leukemiaSEITER, K.Seminars in hematology. 1998, Vol 35, Num 3, pp 22-25, issn 0037-1963, SUP4Article

How I treat newly diagnosed chronic phase CMLCORTES, Jorge; KANTARJIAN, Hagop.Blood. 2012, Vol 120, Num 7, pp 1390-1397, issn 0006-4971, 8 p.Article

Cell Culture Modeling of Genotype-Directed Sensitivity to Selective Kinase Inhibitors: Targeting the Anaplastic Lymphoma Kinase (ALK)SETTLEMAN, Jeff.Seminars in oncology. 2009, Vol 36, Num 2, issn 0093-7754, S36-S41, SUP1Article

Role of c-Met in Cancer: Emphasis on Lung CancerSALGIA, Ravi.Seminars in oncology. 2009, Vol 36, Num 2, issn 0093-7754, S52-S58, SUP1Article

Advanced-phase chronic myeloid leukemiaCORTES, Jorge; KANTARJIAN, Hagop.Seminars in hematology. 2003, Vol 40, Num 1, pp 79-86, issn 0037-1963, 8 p.Article

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patientsHOCHHAUS, Andreas; KANTARJIAN, Hagop.Journal of cancer research and clinical oncology. 2013, Vol 139, Num 12, pp 1971-1984, issn 0171-5216, 14 p.Article

New strategies in chronic myeloid leukemia : PIH: New era of leukemia therapyKANTARJIAN, Hagop M; CORTES, Jorge.International journal of hematology. 2006, Vol 83, Num 4, pp 289-293, issn 0925-5710, 5 p.Article

Beyond chronic myelogenous leukemia: Potential role for imatinib in philadelphia-negative myeloproliferative disordersCORTES, Jorge; KANTARJIAN, Hagop.Cancer. 2004, Vol 100, Num 10, pp 2064-2078, issn 0008-543X, 15 p.Article

Chronic Myelogenous LeukemiaKANTARJIAN, Hagop M; TALPAZ, Moshe.Hematology/oncology clinics of North America. 2004, Vol 18, Num 3, issn 0889-8588, 274 p.Serial Issue

The evolving role of oral topotecanBURRIS, H. A.Seminars in hematology. 1999, Vol 36, Num 4, pp 26-32, issn 0037-1963, SUP8Article

Adult acute lymphocytic leukemia : Future research directionsKANTARJIAN, Hagop M.Hematology/oncology clinics of North America. 2001, Vol 15, Num 1, issn 0889-8588, viii,207-211 [6 p.]Article

Decitabine dosing schedulesKANTARJIAN, Hagop M; ISSA, Jean-Pierre J.Seminars in hematology. 2005, Vol 42, Num 3, pp S17-S22, issn 0037-1963, SUP2Article

Lymphoblastic lymphomaTHOMAS, Deborah A; KANTARJIAN, Hagop M.Hematology/oncology clinics of North America. 2001, Vol 15, Num 1, issn 0889-8588, vi,51-95 [46 p.]Article

Adult acute lymphocytic leukemia : Introduction and questions related to current programsKANTARJIAN, Hagop M.Hematology/oncology clinics of North America. 2000, Vol 14, Num 6, issn 0889-8588, vii,1205-1208 [5 p.]Article

  • Page / 30